Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Jun 14;3(4):1010–1024. doi: 10.1002/cam4.269

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2014 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Kaplan–Meier survival curves for CNS versus skin IVL patients. Compared to skin IVL, CNS IVL had a significantly shorter (A) median time from initial presentation of symptoms to death (18.0 [range 1.0–110.0, n = 112] versus 6.0 [range 0.1–71.1, n = 248] months, respectively [P = 0.0001]), (B) median time from diagnosis to death (23.0 [range 0.1–96.0, n = 110] versus 14.0 [range 0.1–84.0, n = 141] months, respectively [P = 0.0064]), and (C) median time from treatment to death (24.0 [range 0.7–96.0, n = 94] versus 16.0 [0.3–84.0, n = 117] months, respectively [P = 0.0238]). There was no difference between skin and CNS IVL patients with respect to (D) median time from treatment to first. recurrence (6.0 [range 1.0–33.0, n = 21] versus 8.0 [1.0–44.0, n = 16] months, respectively [P = 0.6375]). IVL, intravascular lymphomatosis; CNS, central nervous system.